Skip to content
Westlake BioPartners
  • People
  • Portfolio
  • About
  • News
  • Contact
Westlake BioPartners
  • People
  • Portfolio
  • About
  • News
  • Contact

Investing in People With Vision

It takes a village to bring life-saving medicines to market, so we invest in entrepreneurs to create companies that turn breakthroughs into treatments for patients in need. 

W Hero Image

We Put People First

Westlake BioPartners is a people-first life science VC firm that crafts companies around world-class entrepreneurs. Immersed in the Los Angeles biotech community we helped catalyze, we’re intentionally scaled to incubate only the most promising companies by complementing their teams with personal attention, hands-on support, and connections to the most impactful innovations of our time. We believe it takes more than just great science to make life-changing medicines and by putting people first, we serve the greatest unmet patient needs.

Get to Know Our People

Our Entrepreneurs Making a Difference

Catherine Pearce, CEO

Catherine Pearce,
CEO

AllRock Bio

Advancing impactful therapies for cardio­pulmonary diseases.

Christian Hordo, CEO

Christian Hordo,
CEO

Borealis Biosciences

Next-generation RNA medicines for kidney disease.

Company We’re Proud to Keep

The Westlake Way

We know people are the first and most valuable asset. Our approach focuses on empowering the right entrepreneurs and guiding them through growth from ideation and preclinical research to clinical and commercial impact for the treatment of patients. We’re intentionally scaled to foster close relationships with our founders, take action instead of offer opinions, and deepen harmonious connections in our entrepreneurial network. By committing to personal attention, we provide each member of our concentrated portfolio with equal and essential access to innovation, capital, and community.

Learn About Our Approach

Happenings in Our Network

Portfolio News

Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors

January 12, 2026
Financing led by institutional investors, with participation from new investor Eli...
Read More
Portfolio News

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi

January 12, 2026
Phase 1 study of REX-8756 is well underway following FDA clearance...
Read More
Portfolio News

Recludix Pharma Bolsters Scientific Advisory Board with Acclaimed Leaders in the Fields of Rheumatology, Dermatology and JAK/STAT Biology

January 8, 2026
Recludix Pharma Bolsters Scientific Advisory Board with Acclaimed Leaders in the...
Read More
See All the Latest

A Complementary Community

Where our visionary founders seized the opportunity to propel the Los Angeles biotech ecosystem, we’ve continued to build an increasingly symbiotic and ever-evolving community. From finding the right entrepreneurs to spearhead company formation, to scaling science through phase-appropriate R&D resources, our network provides unique complementary connections. Drawing from these roots, we support people making medical breakthroughs in California and beyond.

Thinking of the next breakthrough?

Join Our Community
  • People
  • Portfolio
  • About
  • News
  • Contact

© 2026 Westlake BioPartners. All Rights Reserved. Privacy Policy